Halozyme Therapeutics (HALO) said late Thursday that argenx (ARGX) received the US Food and Drug Administration's approval for Vyvgart hytrulo prefilled syringe for self-injection to treat adult patients with generalized myasthenia gravis.
The company said the treatment is for anti-acetylcholine receptor antibody-positive patients and adult patients with chronic inflammatory demyelinating polyneuropathy.
The single-dose prefilled subcutaneous injection was developed in Argenx's exclusive partnership with Halozyme.
"We are delighted that Argenx continues to expand use of Halozyme's proven ENHANZE technology to support patient independence and convenience," said Helen Torley, chief executive officer of Halozyme.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.